564 Results for "

β3

" in MedChemExpress (MCE) Product Catalog:
Products (564)

564 Results for "β3" in MCE Product Catalog:

143
143 Publications Verification
Cat. No.: HY-12008
CAS No.: 183319-69-9
Purity:  99.94%
Synonyms: CP-358774 hydrochloride; NSC 718781 hydrochloride; OSI-774 hydrochloride
Target:  

EGFR OAT ERK GSK-3 β-catenin

Research Areas:  

Endocrinology Cancer

Erlotinib (CP-358774) Hydrochloride is a selective, orally active EGFR tyrosine kinase inhibitor. Erlotinib Hydrochloride also acts as a substrate and inhibitor of OATP2B1, with an IC50 of approximately 0.079 μM for inhibiting OATP2B1-mediated uptake of estrone 3-sulfate. Erlotinib Hydrochloride blocks EGFR phosphorylation, downstream signal transduction, as well as the growth and proliferation of cancer cells. Erlotinib Hydrochloride inhibits MMP-10-mediated renal injury, fibrotic lesions, the ERK1/2, GSK-3β and β-catenin signaling pathways, as well as the deposition of fibronectin, α-SMA, collagen and renal injury markers. Erlotinib Hydrochloride is metabolized via CYP3A to produce the active metabolite OSI-420. Erlotinib Hydrochloride can be used in research related to non-small cell lung cancer, gastric cancer, papillary renal cell carcinoma, EGFR inhibitor resistance and renal fibrosis [3] .
loading...
    loading...
143
143 Publications Verification
Cat. No.: HY-50896
CAS No.: 183321-74-6
Synonyms: CP-358774; NSC 718781; OSI-774
Target:  

EGFR OAT ERK GSK-3 β-catenin

Research Areas:  

Endocrinology Cancer

Erlotinib (CP-358774) is a selective, orally active EGFR tyrosine kinase inhibitor. Erlotinib also acts as a substrate and inhibitor of OATP2B1, with an IC50 of approximately 0.079 μM for inhibiting OATP2B1-mediated uptake of estrone 3-sulfate. Erlotinib blocks EGFR phosphorylation, downstream signal transduction, as well as the growth and proliferation of cancer cells. Erlotinib inhibits MMP-10-mediated renal injury, fibrotic lesions, the ERK1/2, GSK-3β and β-catenin signaling pathways, fibronectin, α-SMA, collagen deposition, and renal injury markers. Erlotinib is metabolized via CYP3A to produce the active metabolite OSI-420. Erlotinib can be used in research related to non-small cell lung cancer, gastric cancer, papillary renal cell carcinoma, pancreatic cancer, renal fibrosis, and other conditions [3] .
loading...
    loading...
74
74 Cited Publications
Cat. No.: HY-16143
CAS No.: 199807-35-7
Synonyms: EMD 121974 TFA
Target:  

Integrin Autophagy

Research Areas:  

Cancer

Cilengitide is a potent and selective integrin inhibitor for αvβ3 and αvβ5 receptor, with IC50 values of 4 nM and 79 nM, respectively.
loading...
    loading...
47
47 Cited Publications
Cat. No.: HY-13951
CAS No.: 72795-01-8
Purity:  99.74%
Synonyms: ICI-118551 hydrochloride
Target:  

Adrenergic Receptor

Research Areas:  

Neurological Disease Endocrinology

Zenidolol (ICI-118551) hydrochloride is a highly selective β2 adrenergic receptor antagonist, with Kis of 0.7, 49.5 and 611 nM for β2, β1 and β3 receptors, respectively.
loading...
    loading...
47
47 Cited Publications
Cat. No.: HY-100543
CAS No.: 72795-26-7
Purity:  99.60%
Synonyms: ICI-118551
Zenidolol (ICI-118551) is a selective β2-adrenergic receptor antagonist with Ki values of Zenidolol for β2, β1 and β3 adrenergic receptors of 0.7, 49.5 and 611 nM, respectively. Zenidolol exerts antitumor effects via inducing apoptosis, inhibiting tumor sphere formation, and downregulating the HIF pathway by blocking β2-AR on tumor cells. Zenidolol exhibits a unique pulmonary vessel-specific vasodilatory effect in mouse models. Zenidolol can be used as an intraocular pressure-lowering agent in ophthalmic disease research [3] .
loading...
    loading...
47
47 Cited Publications
Cat. No.: HY-12012
CAS No.: 280744-09-4
Purity:  99.37%
Target:  

GSK-3 Autophagy

Research Areas:  

Neurological Disease Cancer

SB 216763 is potent, selective and ATP-competitive GSK-3 inhibitor with IC50s of 34.3 nM for both GSK-3α and GSK-3β.
loading...
    loading...
34
34 Cited Publications
Cat. No.: HY-10590
CAS No.: 601514-19-6
Purity:  99.20%
Target:  

Wnt GSK-3 Autophagy

Research Areas:  

Neurological Disease Cancer

TWS119 is an inhibitor of GSK-3β, with an IC50 of 30 nM, and activates the wnt/β-catenin pathway.
loading...
    loading...
32
32 Cited Publications
Cat. No.: HY-P0023
CAS No.: 161552-03-0
Target:  

Integrin

Research Areas:  

Cancer

Cyclo(-RGDfK) is a potent and selective inhibitor of the αvβ3 integrin, with an IC50 of 0.94 nM. Cyclo(-RGDfK) potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface .
loading...
    loading...
32
32 Cited Publications
Cat. No.: HY-P0023A
CAS No.: 500577-51-5
Target:  

Integrin

Research Areas:  

Cancer

Cyclo(-RGDfK) TFA is a potent and selective inhibitor of the αvβ3 integrin, with an IC50 of 0.94 nM . Cyclo(-RGDfK) TFA potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface [3].
loading...
    loading...
28
28 Cited Publications
Cat. No.: HY-116771
CAS No.: 183720-02-7
Purity:  99.37%
Target:  

Adrenergic Receptor

Research Areas:  

Metabolic Disease

CL316243 free acid is a highly potent selective β3-adrenoceptor agonist with a EC50 of 3 nM, but is an extremely poor to β1/2- receptors. CL316243 free acid is a effective stimulant of adipocyte lipolysis and increases brown adipose tissue thermogenesis and metabolic rate. CL316243 free acid has the potential for the treatment obesity, diabetes and urge urinary incontinence [3].
loading...
    loading...
28
28 Cited Publications
Cat. No.: HY-116771A
CAS No.: 138908-40-4
Purity:  99.98%
Target:  

Adrenergic Receptor

Research Areas:  

Metabolic Disease

CL316243 is a highly potent selective β3-adrenoceptor agonist with a EC50 of 3 nM, but is an extremely poor to β1/2- receptors .CL316243 is a effective stimulant of adipocyte lipolysis and increases brown adipose tissue thermogenesis and metabolic rate . CL316243 has the potential for the treatment obesity, diabetes and urge urinary incontinence [3].
loading...
    loading...
22
22 Cited Publications
Cat. No.: HY-16294
CAS No.: 603288-22-8
Target:  

GSK-3

Research Areas:  

Cancer

LY2090314 is a potent inhibitor of glycogen synthase kinase-3 (GSK-3) with IC50 values of 1.5 nM and 0.9 nM for GSK-3α and GSK-3β, respectively.
loading...
    loading...
16
16 Cited Publications
Cat. No.: HY-12302
CAS No.: 142273-20-9
Purity:  98.20%
Synonyms: 9-Bromopaullone; NSC-664704
Target:  

CDK GSK-3

Research Areas:  

Cancer

Kenpaullone is a potent inhibitor of CDK1/cyclin B and GSK-3β, with IC50s of 0.4 μM and 23 nM, and also inhibits CDK2/cyclin A, CDK2/cyclin E, and CDK5/p25 with IC50s of 0.68 μM, 7.5 μM, 0.85 μM, respectively. Kenpaullone, a small molecule inhibitor of KLF4, reduces self-renewal of breast cancer stem cells and cell motility in vitro.
loading...
    loading...
15
15 Cited Publications
Cat. No.: HY-N0378
CAS No.: 69-65-8
Synonyms: Mannitol; Mannite
D-Mannitol (Mannitol) is an oral, resistant sugar widely used in the food and pharmaceutical industries to promote the absorption and retention of calcium and magnesium through cecal fermentation, while acting as a osmotic diuretic to reduce tissue edema. D-Mannitol can enhance brown fat formation, improve insulin effect, reduce blood sugar levels, And through the start the β3-adrenergic receptor (β3-AR), PGC1α and PKA induced by means of white fat cells into brown fat cells [3] . D-Mannitol is commonly used to maintain osmotic pressure between the plant cytoplasm and the culture medium and protect cells when the cell wall is weakened or even removed .
loading...
    loading...
15
15 Cited Publications
Cat. No.: HY-12273
CAS No.: 1206711-16-1
Purity:  99.93%
DMH-1 is a selective BMP inhibitor. DMH-1 upregulates the expression of SOX1. DMH-1 increases cardiomyocyte progenitor cells and promotes the differentiation of mouse embryonic stem cells into cardiomyocytes. DMH-1 induces the differentiation of hiPSC-derived neural progenitor cells into β3-tubulin-positive neurons .
loading...
    loading...
15
15 Cited Publications
Cat. No.: HY-11012
CAS No.: 327036-89-5
Purity:  99.76%
Synonyms: GSK-3β Inhibitor I; NP 01139
Target:  

GSK-3

Research Areas:  

Cancer

TDZD-8 is an inhibitor of GSK-3β, with an IC50 of 2 μM; TDZD-8 shows less potent activities against Cdk-1/cyclin B, CK-II, PKA, and PKC, with all IC50s of >100 μM.
loading...
    loading...
13
13 Cited Publications
Cat. No.: HY-100672
CAS No.: 174689-39-5
Purity:  ≥98.0%
SR59230A is a potent, selective, and blood-brain barrier penetrating β3-adrenergic receptor antagonist with IC50s of 40, 408, and 648 nM for β3, β1, and β2 receptors, respectively .
loading...
    loading...
13
13 Cited Publications
Cat. No.: HY-103200
CAS No.: 1135278-41-9
Purity:  99.81%
SR59230A hydrochloride is a potent, selective, and blood-brain barrier penetrating β3-adrenergic receptor antagonist with IC50s of 40, 408, and 648 nM for β3, β1, and β2 receptors, respectively .
loading...
    loading...
12
12 Cited Publications
Cat. No.: HY-N0236
CAS No.: 53947-92-5
Corylin is an orally active flavonoid anti-inflammatory and osteogenic agent that inhibits IL-6-induced STAT3 promoter activity and STAT3 phosphorylation. Corylin also has anticancer, antiatherosclerotic, and ameliorating activity in hyperlipidemia and insulin resistance, inducing adipocyte browning and lipolysis through SIRT1 or β3-AR-dependent pathways [3].
loading...
    loading...
12
12 Cited Publications
Cat. No.: HY-18676
CAS No.: 2070015-22-2
Research Areas:  

Cancer

OSU-T315 (ILK-IN-1) is a small Integrin-linked kinase (ILK) inhibitor with an IC50 of 0.6 μM, inhibiting PI3K/AKT signaling by dephosphorylation of AKT-Ser473 and other ILK targets (GSK-3β and myosin light chain) . OSU-T315 abrogates AKT activation by impeding AKT localization in lipid rafts and triggers caspase-dependent apoptosis in an ILK-independent manner . OSU-T315 causes cell death through apoptosis and autophagy .
loading...
    loading...